Arrowhead Pharmaceuticals saw its stock rise over 21% after positive late-stage trial results for its drug plozasiran, which significantly lowered triglyceride levels in patients with severe hypertriglyceridemia. Chardan Capital raised the price target to $115, suggesting a 26% upside. Despite this optimism, some analysts consider the stock overvalued compared to its intrinsic value. The company plans to seek regulatory approval by year-end, aiming to bring the drug to market soon.
Jefferies increased the price target for Old National Bancorp to $27 from $26 following the bank's strong Q2 results. The bank reported record net income of $249.4 million and EPS of $0.65, surpassing analyst expectations. Key strengths include robus...
Morgan Stanley raised its price target for MGM Resorts International to $43 from $35 but maintained an "Underweight" rating, signaling expected underperformance. MGM is forecasted to report a year-over-year decline in earnings per share to $0.62 in i...
Iberdrola reported Q2 2026 earnings per share of $1.16, meeting analyst expectations, while revenue slightly missed forecasts at $11.92 billion. Despite this, the company achieved a 22% increase in first-half net profit to about $4.95 billion, driven...
West Pharmaceutical Services (WST) is seeing a positive outlook with rising analyst price targets and expected Q2 earnings beat due to high demand for biologics and GLP-1 drug components. The company’s stock has climbed nearly 33% year-to-date, refle...
Grindr Inc's stock rose 11.04% over the past month but declined 8.81% in the last 10 days, reaching a local low. Despite this recent drop, the stock has a strong growth potential of 23.37%, supported by a robust Piotroski Score of 8, indicating solid...
